SCHEMBL904436

SCHEMBL904436

Cc1ncccc1CO

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29674390 1.00
Cyanide SCHEMBL27795915 0.94 MEN1 (0.47)
SCHEMBL6627813 0.83 TKT (0.42)
Bromide SCHEMBL27973798 0.81 TKT (0.41)
Hydrochloric Acid SCHEMBL28854276 0.81 TKT (0.41)
SCHEMBL8663174 0.79 P2RX7 (0.40)
SCHEMBL31421766 0.79
SCHEMBL487765 0.79
SCHEMBL7996407 0.78 P2RX7 (0.39)
SCHEMBL4000359 0.77 P2RX7 (0.44)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 316 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12570666-B2 Furoindazole derivatives BAYER AKTIENGESELLSCHAFT (DE) 2026-03-10 US disclosed
US-12552796-B2 EED inhibitor, and preparation method therefor and use thereof JING MEDICINE TECHNOLOGY (SHANGHAI) LTD. (CN) 2026-02-17 US disclosed
EP-4688754-A1 KCC2 POTENTIATORS AND USES THEREOF Axonis Therapeutics, Inc. (US) 2026-02-11 EP disclosed
EP-4688753-A1 KCC2 POTENTIATORS AND USES THEREOF Axonis Therapeutics, Inc. (US) 2026-02-11 EP disclosed
US-12545684-B2 CDK2 inhibitors BLUEPRINT MEDICINES CORPORATION (US) 2026-02-10 US disclosed
US-20260028351-A1 KCC2 POTENTIATORS AND USES THEREOF AXONIS THERAPEUTICS, INC. 2026-01-29 US disclosed
US-20260028327-A1 KCC2 POTENTIATORS AND USES THEREOF AXONIS THERAPEUTICS, INC. 2026-01-29 US disclosed
EP-4056570-B1 EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF UNIV SHANGHAI TECHNOLOGY (CN) 2026-01-07 EP disclosed
US-20260001864-A1 COMPOUND CONTAINING SULFAMIDE STRUCTURE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF, AND PHARMACEUTICAL COMPOSITION AND APPLICATION NANJING SHUOHUI PHARMATECHNOLOGY CO., LTD (CN) 2026-01-01 US disclosed
US-12486258-B2 Compounds and methods for regulating insulin secretion THE BROAD INSTITUTE, INC. (US) 2025-12-02 US disclosed
WO-1996022775-A1 TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1996-08-01 WO disclosed
US-5541334-A TREATING HIV ABBOTT LABORATORIES (US) 1996-07-30 US disclosed
WO-1996006609-A1 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 1996-03-07 WO disclosed
US-5354866-A Treating HIV infections ABBOTT LABORATORIES (US) 1994-10-11 US disclosed
US-5286721-A Antimicrobial agents FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1994-02-15 US disclosed
EP-0506982-A1 1-AZABICYCLO 3.2.0]HEPT-2-ENE-2-CARBOXYLIC ACID COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1992-10-07 EP disclosed
EP-0486948-A2 Retroviral protease inhibiting compounds ABBOTT LABORATORIES (US) 1992-05-27 EP disclosed
WO-1992006978-A1 1-AZABICYCLO[3.2.0]HEPT-2-ENE-2-CARBOXYLIC ACID COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1992-04-30 WO disclosed
EP-0212748-A2 Photographic product containing a compound which releases a quaternary salt in an alkaline environment, and compounds in compliance therewith POLAROID CORPORATION (US) 1987-03-04 EP disclosed
US-4546198-A Asymmetric synthesis of esters and acids SHELL OIL COMPANY (US) 1985-10-08 US disclosed